PROTOCOL SUMMARY FOR PATIENTS

View Professional Summary

A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113

A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113


Basic Trial Information

Protocol Phase:Phase I
Study Category:Treatment
Current Protocol StatusActive
Age18 and over
Protocol SponsorPharmaceutical/Industry
Primary IDAP26113-11-101
Other IDNCT01449461
Special Category

TRIAL DESCRIPTION

Purpose:
Eligibility:
Treatment Intervention:
Patient Disclaimer: